← Back to Analyst Consensus 
KYTX Buy
Kyverna Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 12
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 18, 2026 (23 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jun 3, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 15, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 13, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| Apr 23, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Dec 16, 2025 | Wells Fargo | maintain | Overweight → Overweight | $33 | 54% |
| Dec 4, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $25 | 54% |
| Oct 30, 2025 | Wells Fargo | maintain | Overweight → Overweight | $31 | 54% |
| Oct 27, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $20 | 44% |
| Oct 8, 2025 | Wells Fargo | maintain | Overweight → Overweight | $27 | 54% |
| Aug 29, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $10 | 44% |
| Aug 20, 2025 | William Blair | initiate | — → Outperform | $0 | 48% |
| May 27, 2025 | HC Wainwright & Co. | upgrade | Neutral → Buy | $5 | 44% |
| Apr 3, 2025 | HC Wainwright & Co. | maintain | Neutral → Neutral | $4 | 44% |
| Apr 1, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $20 | 54% |
| Nov 20, 2024 | HC Wainwright & Co. | maintain | Neutral → Neutral | $6 | 44% |
| Nov 15, 2024 | Wells Fargo | maintain | Overweight → Overweight | $24 | 54% |
| Oct 10, 2024 | UBS | initiate | — → Buy | $13 | 54% |
| Sep 19, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $7 | 44% |
| Aug 15, 2024 | HC Wainwright & Co. | maintain | Neutral → Neutral | $7 | 44% |
| Jul 31, 2024 | JP Morgan | maintain | Overweight → Overweight | $33 | 55% |
| Jul 16, 2024 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $8 | 44% |
| Jul 3, 2024 | HC Wainwright & Co. | initiate | — → Neutral | $8 | 44% |
| Mar 4, 2024 | JP Morgan | initiate | — → Overweight | $39 | 55% |
| Mar 4, 2024 | Morgan Stanley | initiate | — → Overweight | $40 | 54% |
Price Target Trend
May 6, 2026 Latest: $30.4 Oct 24, 2026
EPS Estimates
0q $-0.69
Lo: $-0.77 Hi: $-0.65
5 analysts ▲3
+1y $-3.17
Lo: $-3.74 Hi: $-2.71
5 analysts 0y $-2.77
Lo: $-3.02 Hi: $-2.62
5 analysts ▲3
+1q $-0.80
Lo: $-0.99 Hi: $-0.68
5 analysts ▲2
Cross-Platform Signals
No cross-platform signals in the last 90 days